Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis

NCT03893565 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

104

Enrollment

INDUSTRY

Sponsor class

Stopped The trial was stopped based on the assessment of clinical data.

Conditions

Colitis, Ulcerative

Interventions

DRUG: GSK2831781 - Double Blind Phase
DRUG: Placebo
DRUG: GSK2831781 - Open Label phase

Sponsor

GlaxoSmithKline